27 results
Thumbnail

D1.481 - Prevalence of Immunoglobulin Deficiency in Patients with Chronic Rhinosinusitis Followed in a Tertiary Referral Center

Thumbnail

D1.487 - Evaluation of Large Language Models in Otolaryngology: Accuracy on Structured Question Banks and S.C.O.R.E.-Based Interpretation of Guidelines and Consensus Statements

Thumbnail

D1.485 - Characterization of CRSwNP and associated Type 2 or Respiratory comorbidities in the biological era in Spain - The POLARIS study

Thumbnail

D1.486 - Epidemiological Investigation of Pollen induced Allergic Diseases in China

Thumbnail

D1.489 - The establishment and characteristics of type 2 inflammation in nasal organoids

Thumbnail

D1.490 - Dupilumab in the treatment of Severe Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in Cystic Fibrosis patients

Thumbnail

D1.492 - Efficacy and safety of a combined nasal spray with a fixed dose of mometasone and olopatadine for the treatment of allergic rhinitis in pets under save ongoing exposure to epidermal allergens

Thumbnail

D1.493 - Circulating Exosomal miR-200 Family Downregulation in Allergic Rhinitis

Thumbnail

- D1.532 - Phenotypic and Functional Comparison of LAD2, HMC-1.2, and Primary Human Mast Cells

Thumbnail

- D1.529 - Evaluating the Disease-Modifying Potential of Elenestinib, a Highly Potent and Selective Tyrosine Kinase Inhibitor, in Patients With Indolent Systemic Mastocytosis: An Update on the Pivotal HARBOR Study

Thumbnail

- D1.530 - Patient Experience of Most Burdensome Nonadvanced Systemic Mastocytosis Symptoms From the Pivotal Summit Trial of Bezuclastinib

Thumbnail

- D1.531 - Avapritinib in Indolent Systemic Mastocytosis: Real-world Data from a Greek Case Series

Thumbnail

- D1.533 - Systemic mastocytosis despite normal baseline tryptase: a diagnostic pitfall in recurrent life-threatening anaphylaxis

Thumbnail

D2.449 - Patients with Inadequately Controlled CRSwNP and Blood Eosinophil Count ≥150 cells/µL Experience Benefit with Depemokimab: An Analysis of Data from the Integrated ANCHOR-1/-2 Studies

Thumbnail

D2.447 - Phenotyping of Chronic T2 Inflammatory Diseases of the Nose and Paranasal Sinuses and the Algorithm for Biologic Therapy Selection

Thumbnail

D2.448 - Recommendations on Patient Education for Biological Therapy in CRSwNP – An EAACI Position Paper

Thumbnail

D2.450 - EUFOREA/EPOS Criteria Applied to a Diverse CRSwNP Cohort: Post Hoc Findings from Twice-Yearly depemokimab ANCHOR-1/-2 trials

Thumbnail

D2.451 - Real-life upper and lower airway outcomes of long-term dupilumab treatment in patients with severe chronic rhinosinusitis with nasal polyps

Thumbnail

D2.452 - Real-World Trends in the Epidemiology and Burden of Chronic Rhinosinusitis with Nasal Polyps Over Time in Germany Reveal Increasing Prevalence and Low Biologic Use

Thumbnail

D2.453 - Olfactory outcomes of dupilumab in patients with CRSwNP: A real-world prospective study